This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amedisys (AMED) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of +10.79% and +2.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Brookdale's Occupancy Registers a Rise to 80.5% in June 2025
by Zacks Equity Research
BKD's June occupancy improves 230 bps year over year to 80.5%, driven by stronger move-ins and move-out activity across its senior living communities.
ADUS vs. USPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Do Options Traders Know Something About Addus HomeCare Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ADUS stock based on the movements in the options market lately.
BTSG Raises 2025 Financial Outlook: What's Backing It?
by Sridatri Sarkar
BrightSpring boosts 2025 guidance as Pharmacy and Provider segments post strong gains and margin initiatives take hold.
BrightSpring's Home Health Arm Soars: What's Powering Growth?
by Sridatri Sarkar
BTSG's Home Health Care Q1 2025 sales surge 21%, fueled by Medicare Advantage gains and high patient satisfaction.
BrightSpring's Care Ratings Climb: Is Its Lead Sustainable?
by Sridatri Sarkar
BTSG boosts care quality with tech upgrades, earning top ratings and patient satisfaction across all segments.
Implied Volatility Surging for Addus HomeCare Stock Options
by Zacks Equity Research
Investors need to pay close attention to ADUS stock based on the movements in the options market lately.
Addus HomeCare (ADUS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Addus HomeCare (ADUS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Addus HomeCare (ADUS) Beats Q1 Earnings Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 6.77% and 0.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Elanco Animal Health (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Humana Beat Q1 Earnings Estimates on Growing Premiums?
by Zacks Equity Research
HUM's first-quarter results are likely to benefit from higher Medicare stand-alone PDP revenues.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Addus HomeCare (ADUS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Addus HomeCare (ADUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HCA Healthcare Q1 Earnings Beat on Growing Patient Volumes
by Zacks Equity Research
HCA continues to witness growth in reported and same-facility admissions. The company reaffirms 2025 guidance.
Molina Healthcare Q1 Earnings Beat Estimates on Growing Premiums
by Zacks Equity Research
MOH continues to expect 2025 premium revenues to be around $42 billion.
Elevance Health's Q1 Earnings Beat Estimates on Rising Premiums
by Zacks Equity Research
ELV continues to witness significant growth in Q1 revenues. However, its operating costs surge.
CYH to Sell Stake in Cedar Park Regional to Ascension in $460M Deal
by Zacks Equity Research
Community Health is set to divest an 80% ownership stake in Cedar Park Regional to Ascension Health.
Zacks Industry Outlook Highlights DaVita, Encompass Health, Option Care Health and Addus HomeCare
by Zacks Equity Research
DaVita, Encompass Health, Option Care Health and Addus HomeCare have been highlighted in this Industry Outlook article.
Addus HomeCare (ADUS) Surges 4.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Addus HomeCare (ADUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
4 Stocks to Watch in a Dynamic Outpatient Home Health Industry
by Debanjana Dey
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DVA, EHC, OPCH and ADUS are well-poised to gain.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Addus HomeCare (ADUS) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Addus HomeCare (ADUS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
UnitedHealth's Optum Rx & EPN Team Up for Fairer Pharmacy Payments
by Zacks Equity Research
UNH and EPN join forces to enhance pharmacy reimbursement, ensuring fair payments and better stability for independent pharmacies.
Humana's CenterWell Launches Gladstone Walmart Location for Seniors
by Zacks Equity Research
The easy accessibility for patients will give HUM a competitive edge over other senior-focused healthcare providers.